Company intelligence / Profile preview

Immunomedics

Morris Plains, New Jersey, United Statesgilead.com ↗

Ownership: Public · IMMU
Employees: ~500
Development stage: Commercial

Overview

Immunomedics developed Trodelvy™ (sacituzumab govitecan-hziy), a first-in-class Trop‑2-directed ADC approved for third-line or later metastatic triple-negative breast cancer. The company had ongoing registrational studies in HR+/HER2– metastatic breast cancer and urothelial carcinoma, with clinical activity demonstrated across multiple other solid tumor types. Trodelvy showed significant efficacy benefit versus chemotherapy and was expected to become a standard of care in advanced TNBC.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

1 asset

sacituzumab govitecan

Commercial

Indications: Metastatic triple-negative breast cancer, HR+/HER2- breast cancer, Bladder cancer, Non-small cell lung cancer

Partnerships

Samsung Biologics as CMO for manufacturing support before the acquisition; no major pharma partnerships disclosed beyond parent company post-acquisition.

Financials

Market cap: $218.3M
Total revenue: $3.8M
Enterprise value: $437.2M

Beyond the preview

Go deeper on Immunomedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunomedics.

Explore the full profile